Urothelial carcinoma of the urinary bladder Cancer Malignant neoplasm of bladder
Conditions
Interventions
RNA-sequencing of bladder tumours and molecular subtyping and assessment of molecular grade. Patients will be followed up for at least two years after inclusion to assess progression-free survival.
Sponsors
Skåne University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Bladder cancer subjected to transurethral resection of the tumour (TURB)
Exclusion criteria
Exclusion criteria: Does not meet inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Molecular subtype and grade. The timepoints for assessment of the primary and secondary outcomes will be standardised according to the Swedish national guidelines for bladder cancer regarding recommended follow-up intervals. For the study population this means control with cystoscopy every third month for two years, every sixth month the following three years and then annually with a lifelong follow up. | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival. The timepoints for assessment of the primary and secondary outcomes will be standardised according to the Swedish national guidelines for bladder cancer regarding recommended follow-up intervals. For the study population this means control with cystoscopy every third month for two years, every sixth month the following three years and then annually with a lifelong follow up. | — |
Countries
Sweden
Outcome results
None listed